Teva Pharmaceutical Industries' (TEVA) unit Teva Pharmaceuticals said Wednesday that the US Food and Drug Administration has approved Ajovy for the preventive treatment of episodic migraine in children and adolescents aged 6-17 years who weigh 45 kilograms or more.

Preventive treatment may help decrease the frequency of migraine attacks, the company said, adding Ajovy is given once a month and available for in-office or at home use.

Teva shares were rising 1.1% in recent trading.

Price: 15.89, Change: +0.17, Percent Change: +1.11